產(chǎn)品詳情
簡單介紹：
Anti-MFHA1/Malignant fibrous histiocytoma抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-MFHA1/Malignant fibrous histiocytoma抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-MFHA1/Malignant fibrous histiocytoma
Cat. Number:
Anti-MFHA1/Malignant fibrous histiocytoma抗體KL-18640R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Identified in a human 8p amplicon, this gene is a potential oncogene whose expression is enhanced in some malignant fibrous histiocytomas (MFH). The primary structure of its product includes an ATP/GTP-binding site, threeAnti-MFHA1/Malignant fibrous histiocytoma抗體 leucine zipper domains, and a leucine-rich tandem repeat, which are structural or functional elements for interactions among proteins related to the cell cycle, and which suggest that overexpression might be oncogenic with respect to MFH. [provided by RefSeq, Jul 2008]
Also known as:
Malignant fibrous histiocytoma-amplified sequence 1; Malignant fibrous histiocytoma-amplified sequence with leucine-rich tandem repeats 1; Anti-MFHA1/Malignant fibrous histiocytoma抗體MFHA1_HUMAN; Mfhas1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Dog, .
●
Immunogen: KLH conjugatedAnti-MFHA1/Malignant fibrous histiocytoma抗體 synthetic peptide derived from human MFHA1/Malignant fibrous histiocytoma.
●
Predicted Molecular Weight: 117kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-MFHA1/Malignant fibrous histiocytoma抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-MFHA1/Malignant fibrous histiocytoma抗體
Optimal working dilutions must be determined by the end user.
